Fedratinib Hydrochloride and Ventavis
Determining the interaction of Fedratinib Hydrochloride and Ventavis and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. In clinical trials for pulmonary hypertension, patients received concomitant anticoagulants and/or nonsteroidal anti-inflammatory agents without evidence of increased bleeding. MANAGEMENT: Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. References "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA. "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC. "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.
Professional:MONITOR: Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. In clinical trials for pulmonary hypertension, patients received concomitant anticoagulants and/or nonsteroidal anti-inflammatory agents without evidence of increased bleeding.
MANAGEMENT: Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
- "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.
- "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.
- "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib Hydrochloride-Ventolin
- Fedratinib Hydrochloride-Ventolin HFA
- Fedratinib Hydrochloride-Ventolin Inhalation
- Fedratinib Hydrochloride-Ventolin Inhaler
- Fedratinib Hydrochloride-Ventolin Nebules P.F.
- Fedratinib Hydrochloride-Ventolin Respirator
- Ventavis-Feiba
- Ventavis-Feiba NF
- Ventavis-Feiba VH Immuno
- Ventavis-Feiba-VH
- Ventavis-Felbamate
- Ventavis-Felbamate Oral Suspension